Our cloud-based library of optical fingerprints, powered by photonics and AI, provides non-invasive tracking, screening and stratification for drug discovery, adapted to each clinical trial needs.
Efficient. Flexible. Patient-centric.
Requires only microlitres of blood
Allows for label free flexibility on targets
Takes <10 seconds from start to finish
Requires no consumables, only Light and AI
How can we help?
Our blood-based screening test stratifies patients for clinical trials, removing heterogeneity due to pathophysiology, disease stage or degree of progression.
The iLoF Platform offers:
40% cost savings
70% reduction of time spent on screenings
A non-invasive process for patient convenience
A pool of more qualified candidates, improving trial outcomes
Paving the way for personalised medicine
Forecasting clinical outcomes and predicting severity of symptoms
Stratifying cancer subtypes allowing for design and delivery of tailored treatments
Differentiating between ischemic and hemorrhagic stroke patients for timely clinical management